BioSpace News Archive

On Wednesday, December 12, the New York City Skyline will have five buildings light up for one night to support one cause!

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science

The Biotechnology Innovation Organization (BIO) today announced preliminary programing for the upcoming BIO CEO & Investor Conference to be held February 11-12, 2019 in New York City.

ObsEva SA (NASDAQ: OBSV / SIX: OBSN), today announced initiation of the IMPLANT 4 Phase 3 clinical trial of its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology (ART), or in-vitro fertilization (IVF).

Endo International plc announced today that members of management will participate in a fireside chat at the Bank of America Merrill Lynch Leveraged Finance Conference in Boca Raton, Florida on Tuesday, December 4, 2018 at 9:30 a.m. ET.

At a meeting with analysts and investors at its Investor Day tomorrow, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, will discuss the company’s two-point strategy and range of initiatives underway to accelerate growth and drive operational excellence, and also will outline its near-and long-term financial outlook.

American Kratom Association Requests FDA to Retract Kratom Scheduling Recommendation

Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead products Buvidal® Weekly and Buvidal® Monthly (CAM2038) for maintenance treatment of opioid dependence within a framework of medical, social and psychosocial support.

The Canadian Medical Association (CMA) joins the Canadian Public Health Association (CPHA) in calling for the implementation of the Canada-specific recommendations presented in the Lancet Countdown on Health and Climate Change.

Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).